No profile data available.
Nectar Lifesciences Limited (NECLIFE.NS) is a healthcare company in the drug manufacturing contractors industry, based in Chandigarh, India, with about 111 full-time employees.
It reported revenue of 16.70 billion INR for fiscal year 2025, down 0.8% from fiscal year 2024, and net income of -1.14 billion INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 0 INR, down 100.0% from a year before. India was its largest region in fiscal year 2025, with 61% of revenue. Its market capitalization was 1.97 billion INR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally.
Nectar Lifesciences reported 16.70 billion INR in revenue for fiscal year 2025, down 0.8% from 16.84 billion INR in fiscal year 2024. In Q3 2026 revenue was 0 INR.
India: 61% of revenue by region in fiscal year 2025, followed by Outside India (39%).
1.97 billion INR as of October 9, 2026.
Listed companies of a similar size in the same industry (drug manufacturing contractors) include Brooks Laboratories Limited (BROOKS.NS), Coral Laboratories Limited (CORALAB.BO), Syschem (India) Limited (SYSCHEM.BO), Oxygenta Pharmaceutical Limited (OXYGENTAPH.BO).